Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Stroes

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
International Journal of Nanomedicine|April 28, 2023
Comparative in vitro and in vivo Evaluation of Different Iron Oxide-Based Contrast Agents to Promote Clinical Translation in Compliance with Patient SafetyHarald Unterweger, Christina Janko, Tamara Folk, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2010
Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapyFiona C Lampe, Daniel A Duprez, Lewis H Kuller, et al.
Atherosclerosis|February 11, 2026
Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension studyFrederick J Raal, Susanne Greber-Platzer, Laurens F Reeskamp, et al.
European Heart Journal Open|September 4, 2025
Fuelling aortic stenosis: the integral role of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3-mediated glycolysis in Lp(a)-induced valve inflammationMerel Peletier, Lubna Ali, Kim Dzobo, et al.
Antiviral Therapy|November 21, 2007
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patientsManon van der Lee, Raaj Sankatsing, Emile Schippers, et al.
Cell Reports|April 2, 2026
Intravenous injection of lipid-free apolipoprotein A-I dampens inflammation by reprogramming macrophage functionRadjesh Bisoendial, Anna Kusienicka, Matthias Wielscher, et al.
Plos Medicine|November 5, 2004
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Frank van Leth, Prahpan Phanuphak, Erik Stroes, et al.
JACC. Advances|June 28, 2024
The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaFrederick J Raal, Robert S Rosenson, Laurens F Reeskamp, et al.
Clinical Cardiology|March 7, 2016
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) TrialSteven E Nissen, Ricardo E Dent-Acosta, Robert S Rosenson, et al.
Cardiovascular Research|December 12, 2018
Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of CardiologyJosé Tuñón, Lina Badimón, Marie-Luce Bochaton-Piallat, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
International Journal of Nanomedicine|April 28, 2023
Comparative in vitro and in vivo Evaluation of Different Iron Oxide-Based Contrast Agents to Promote Clinical Translation in Compliance with Patient SafetyHarald Unterweger, Christina Janko, Tamara Folk, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2010
Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapyFiona C Lampe, Daniel A Duprez, Lewis H Kuller, et al.
Atherosclerosis|February 11, 2026
Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension studyFrederick J Raal, Susanne Greber-Platzer, Laurens F Reeskamp, et al.
European Heart Journal Open|September 4, 2025
Fuelling aortic stenosis: the integral role of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3-mediated glycolysis in Lp(a)-induced valve inflammationMerel Peletier, Lubna Ali, Kim Dzobo, et al.
Antiviral Therapy|November 21, 2007
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patientsManon van der Lee, Raaj Sankatsing, Emile Schippers, et al.
Cell Reports|April 2, 2026
Intravenous injection of lipid-free apolipoprotein A-I dampens inflammation by reprogramming macrophage functionRadjesh Bisoendial, Anna Kusienicka, Matthias Wielscher, et al.
Plos Medicine|November 5, 2004
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Frank van Leth, Prahpan Phanuphak, Erik Stroes, et al.
JACC. Advances|June 28, 2024
The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaFrederick J Raal, Robert S Rosenson, Laurens F Reeskamp, et al.
Clinical Cardiology|March 7, 2016
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) TrialSteven E Nissen, Ricardo E Dent-Acosta, Robert S Rosenson, et al.
Cardiovascular Research|December 12, 2018
Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of CardiologyJosé Tuñón, Lina Badimón, Marie-Luce Bochaton-Piallat, et al.
Pageof 5